Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALNY, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vutrisiran FDA approved Jun 2022 · Amvuttra |
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Phase 3 · NCT07223203 | Recruiting |
| Patisiran FDA approved Aug 2018 · Onpattro |
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 · NCT03997383 | Completed |
| Lumasiran FDA approved Nov 2020 · Oxlumo |
Primary Hyperoxaluria Type 1 | Phase 3 · NCT04152200 | Completed |
| Givosiran FDA approved Nov 2019 · Givlaari |
Acute Hepatic Porphyria | N/A · NCT04056481 | Approved for marketing |
| Zilebesiran | High Risk Cardiovascular Disease | Phase 3 · NCT07181109 | Recruiting |
| Nucresiran | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Phase 3 · NCT07223203 | Recruiting |
| Cemdisiran | IgA Nephropathy (IgAN) | Phase 2 · NCT03841448 | Terminated |
| Elebsiran | Chronic Hepatitis B | Phase 2 · NCT04412863 | Completed |
| Peginterferon Alfa-2a | Chronic Hepatitis B | Phase 2 · NCT04412863 | Completed |
| Olmesartan | Hypertension | Phase 2 · NCT05103332 | Completed |
| Mivelsiran | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Phase 2 · NCT07636811 | Recruiting |
| ALN-2232 | Obesity | Phase 1/2 · NCT07463846 | Recruiting |
| Amlodipine | Hypertension | Phase 2 · NCT05103332 | Completed |
| ALN-KHK | Type 2 Diabetes Mellitus (T2DM) | Phase 1/2 · NCT05761301 | Terminated |
| ALN-4324 | Obese or Overweight Healthy Volunteers | Phase 1/2 · NCT06845202 | Active not recruiting |
| ALN-6400 | Hereditary Hemorrhagic Telangiectasia | Phase 1/2 · NCT06659640 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not ALNY's own candidates): Tirzepatide, Indapamide, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALNY holds $3.6B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALNY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Capital World Investors | Institution (13G, 5%+) | 13,934,539 | 10.40% | 2026-09-30 |
| FMR LLC | Institution (13G, 5%+) | 12,675,053 | 9.46% | 2026-09-30 |
| Capital Research Global Investors | Institution (13G, 5%+) | 10,940,905 | 8.17% | 2026-09-30 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 10,017,904 | 7.48% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 7,104,536 | 5.30% | 2026-03-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 6,732,082 | 5.03% | 2026-09-30 |
| Yvonne Greenstreet Chief Executive Officer, Director · +141,171 options |
Insider | 96,209 | 0.07% | 2026-09-19 |
| Jeffrey V. Poulton EVP, Chief Financial Officer · +10,480 options |
Insider | 61,862 | 0.05% | 2026-03-04 |
| Tolga Tanguler EVP, Chief Commercial Officer · +10,480 options |
Insider | 34,297 | 0.03% | 2026-03-04 |
| David E I Pyott Director · +1,441 options |
Insider | 33,262 | 0.02% | 2026-11-10 |
| Amy W Schulman Director · +1,802 options |
Insider | 25,959 | 0.02% | 2026-11-09 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research · +8,105 options |
Insider | 21,106 | 0.02% | 2026-03-04 |
Share count 133,937,576 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALNY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →